Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Rare Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06746766
What this trial is testing

Registry Study on Rare Cancers in Korea

Who this might be right for
Rare Cancer
Yonsei University 500
Testing effectiveness (Phase 2)Study completedNCT00141765
What this trial is testing

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

Who this might be right for
Wilms TumorFibrosarcomaCarcinoma, Round Cell+2 more
University of Michigan Rogel Cancer Center 25
Not applicableLooking for participantsNCT06856902
What this trial is testing

BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe

Who this might be right for
Cardiovascular DiseasesEndocrinologyInmunology+3 more
Technical University of Madrid 3,100
Large-scale testing (Phase 3)Looking for participantsNCT05770544
What this trial is testing

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Not applicableLooking for participantsNCT07665307
What this trial is testing

Delayed Toxicities Post-CAR-T

Who this might be right for
Multiple Myeloma
Icahn School of Medicine at Mount Sinai 30
Testing effectiveness (Phase 2)Study completedNCT04790409
What this trial is testing

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Lung Cancer
Zhejiang Cancer Hospital 21
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Not applicableUnknownNCT02299622
What this trial is testing

Personalized Sequence for Thoracic, Esophageal, and H&N Cancer

Who this might be right for
Lung Cancer
Samsung Medical Center 200
Testing effectiveness (Phase 2)Ended earlyNCT00958841
What this trial is testing

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Who this might be right for
Pancreatic NeoplasmPituitary NeoplasmNelson Syndrome+1 more
Novartis Pharmaceuticals 118
Not applicableLooking for participantsNCT02705846
What this trial is testing

Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations

Who this might be right for
Prostate Cancer
Institute of Cancer Research, United Kingdom 4,260
Testing effectiveness (Phase 2)Looking for participantsNCT03866382
What this trial is testing

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Who this might be right for
Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more
National Cancer Institute (NCI) 314
Testing effectiveness (Phase 2)Ended earlyNCT05017103
What this trial is testing

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Who this might be right for
Locally Advanced Undifferentiated Pleomorphic SarcomaMetastatic Undifferentiated Pleomorphic SarcomaRecurrent Undifferentiated Pleomorphic Sarcoma+1 more
M.D. Anderson Cancer Center 6
Not applicableStudy completedNCT01119586
What this trial is testing

Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia
Children's Oncology Group 350
Testing effectiveness (Phase 2)Looking for participantsNCT07309770
What this trial is testing

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Who this might be right for
Urachal CancerAdvanced Solid Tumor CancerAntibody-drug Conjugates
Sheng Zhang 90
Not applicableStudy completedNCT03251989
What this trial is testing

Rare CNS Tumors Outcomes &Risk

Who this might be right for
High Grade MeningiomaEpendymomaMedulloblastoma+2 more
National Cancer Institute (NCI) 326
Not applicableLooking for participantsNCT03854318
What this trial is testing

Longitudinal Studies of Patient With FPDMM

Who this might be right for
Inherited Hematological DiseasesRare DiseasesFPDMM
National Human Genome Research Institute (NHGRI) 1,000
Not applicableLooking for participantsNCT07524114
What this trial is testing

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

Who this might be right for
Breast CancerLung CancerMelanoma+7 more
University Health Network, Toronto 7,000
Not applicableLooking for participantsNCT05350761
What this trial is testing

Rare Tumors and Cancer Predisposition in Individuals and Families

Who this might be right for
CancerHereditary NeoplasmsGenetic Predisposition to Cancer+1 more
National Cancer Institute (NCI) 500
Not applicableLooking for participantsNCT05046080
What this trial is testing

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Who this might be right for
Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
M.D. Anderson Cancer Center 70
Large-scale testing (Phase 3)UnknownNCT04951648
What this trial is testing

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Next Page